Supping with the Devil? The role of law in promoting tobacco harm reduction using low nitrosamine smokeless tobacco products

被引:21
作者
Hall, W. [1 ]
Gartner, C. [1 ]
机构
[1] Univ Queensland, Sch Populat Hlth, Herston, Qld 4006, Australia
基金
英国医学研究理事会;
关键词
Tobacco harm reduction; Snus; Smokeless tobacco; Tobacco industry; Smoking; SWEDISH SNUS; SMOKING; NICOTINE; CANCER; RISK; INITIATION; CESSATION; HEALTH;
D O I
10.1016/j.puhe.2008.12.018
中图分类号
R1 [预防医学、卫生学];
学科分类号
1004 ; 120402 ;
摘要
In Sweden, male cigarette smoking has declined as snus, a smokeless tobacco product which is low ill Carcinogenic nitrosamines, has gained popularity among male tobacco users. Epidemiological modelling based on the Swedish experience indicates that there Would be major Public health gains if a Substantial number Of current smokers in other Countries could also be persuaded to switch to this product. This form of 'tobacco harm reduction' is very controversial in the public health community for many reasons. These include: Objections ill principle to the use of less harmful but still addictive nicotine products: uncertainties about the long-term effects of these products on health; doubts about the likely interest ill and uptake of these products among existing smokers: concerns that increasing the availability of these products Will increase the number of new tobacco users and eventually the number of smokers in the population; and anxiety about how the tobacco industry may use these products to undermine Current tobacco control policies. This paper concludes with Suggestions for a graduated series of policies that may allow exploration of the Public health costs and benefits of encouraging smokers to switch to snus. (c) 2009 The Royal Society for Public Health. Published by Elsevier Ltd. All rights reserved.
引用
收藏
页码:287 / 291
页数:5
相关论文
共 52 条
[1]   Smokeless tobacco and cardiovascular disease [J].
Asplund, K .
PROGRESS IN CARDIOVASCULAR DISEASES, 2003, 45 (05) :383-394
[2]   Smokeless tobacco, smoking cessation and harm reduction: an economic analysis [J].
Ault, RW ;
Ekelund, RB ;
Jackson, JD ;
Saba, RP .
APPLIED ECONOMICS, 2004, 36 (01) :17-29
[3]  
Benowitz N L., 2000, Nicotine and Public Health, P65
[4]   Pharmacology of nicotine: Addiction and therapeutics [J].
Benowitz, NL .
ANNUAL REVIEW OF PHARMACOLOGY AND TOXICOLOGY, 1996, 36 :597-613
[5]  
Berridge V., 2007, Marketing Health: Smoking the Discourse of Public Health in Britain, 1945-2000
[6]  
[Bonnie R.J. Institute of Medicine Institute of Medicine], 2007, ENDING TOBACCO PROBL
[7]  
Brandt AllanM., 2007, CIGARETTE CENTURY
[8]   Mandated lowering of toxicants in cigarette smoke: a description of the World Health Organization TobReg proposal [J].
Burns, D. M. ;
Dybing, E. ;
Gray, N. ;
Hecht, S. ;
Anderson, C. ;
Sanner, T. ;
O'Connor, R. ;
Djordjevic, M. ;
Dresler, C. ;
Hainaut, P. ;
Jarvis, M. ;
Opperhuizen, A. ;
Straif, K. .
TOBACCO CONTROL, 2008, 17 (02) :132-141
[9]  
Chapman S, 2007, PUBLIC HEALTH ADVOCACY AND TOBACCO CONTROL: MAKING SMOKING HISTORY, P1, DOI 10.1002/9780470692479
[10]   Is smokeless tobacco a risk factor for coronary heart disease? A systematic review of epidemiological studies [J].
Critchley, JA ;
Unal, B .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2004, 11 (02) :101-112